Meet Embecta! Becton Dickinson Completes Diabetes Spin-Off
Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.
You may also be interested in...
In this Medtech Insight special podcast recorded in June, BD’s chief executive since January 2020, Tom Polen, describes how he has built on the legacy of his predecessor to ensure the $20bn company he now heads can grow sustainably to meet the changing demands of the health care market and the modern challenges medtech managers must face.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Executives On The Move will be running to a monthly schedule from now, with this edition covering medtech's executive changes for April.